Treatment Information

Back

Liver Cancer treatment details. Chemotherapy, Biologic therapy.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Philadelphia, PA
Treatments:Chemotherapy, Biologic therapyHospital:Abramson Cancer Center, University of Pennsylvania
Drugs:Journal:Link
Date:Jul 2011

Description:

Patients:
This phase II study involved 40 patients with advanced hepatocellular carcinoma who had not received prior chemotherapy. The median patient age was 56 years and 80% of the patients were male.

Treatment:
Patients were treated with the biologic therapy agent bevacizumab and the chemotherapy agents capecitabine and oxaliplatin.

Toxicities:
There was 1 treatment-related death due to gastric perforation and sepsis (blood infection). Grade 3/4 peripheral neurotoxicity, fatigue, and diarrhea were also reported.

Results:
The median progression-free and overall survival rates were 6.8 and 9.8 months, respectively.

Support:
This study was supported by Genentech, makers of bevacizumab (brand name: Avastin).

Correspondence: Dr. Weijing Sun; email: [email protected]



Back